北陆药业(300016) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥183,930,040.70, a decrease of 17.18% compared to ¥222,075,960.67 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was ¥39,263,324.48, down 22.18% from ¥50,451,938.09 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥33,601,161.26, reflecting a decline of 26.73% compared to ¥45,856,829.98 in the previous year[4] - Total revenue for the current period was CNY 183,930,040.70, a decrease of 17.1% compared to CNY 222,075,960.67 in the previous period[28] - Operating profit for the current period was CNY 40,011,884.74, a decline of 24.1% from CNY 52,626,205.95[28] - Net profit for the current period was CNY 34,776,332.03, down 23.2% from CNY 45,325,558.55 in the previous period[30] - Earnings per share decreased to CNY 0.0800 from CNY 0.1032, reflecting a decline of 22.4%[30] Cash Flow - The net cash flow from operating activities was ¥21,378,261.26, a significant drop of 54.71% from ¥47,200,999.98 in the same quarter last year[4] - Total cash inflow from operating activities was ¥228,618,017.48, while cash outflow was ¥207,239,756.22, resulting in a net cash inflow[32] - Cash flow from investing activities showed a net outflow of ¥530,210,081.18, worsening from a net outflow of ¥424,149,576.66 in the previous period[34] - Cash inflow from financing activities was ¥57,276,000.00, with a net cash flow of ¥55,518,667.59 after accounting for cash outflows[34] - The ending balance of cash and cash equivalents decreased to ¥407,009,554.60 from ¥615,431,981.12, reflecting a decline of 33.8%[34] - The company received ¥11,514,250.11 in other operating cash, significantly up from ¥3,778,962.97 in the previous period, indicating a 204.5% increase[32] - Payments for goods and services amounted to ¥107,579,401.07, which is a 37.8% increase from ¥78,120,254.56 in the previous period[32] - The company’s cash flow from financing activities included dividend payments of ¥1,757,332.41, down from ¥3,438,433.51 in the previous period[34] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,967,839,366.78, an increase of 2.24% from ¥2,902,882,759.22 at the end of the previous year[4] - Total assets increased to CNY 2,967,839,366.78 from CNY 2,902,882,759.22, representing a growth of 2.2%[25] - Total liabilities rose to CNY 847,710,716.82, an increase of 3.6% from CNY 818,223,668.61[25] - Non-current assets totaled CNY 1,593,629,157.99, slightly down from CNY 1,596,804,307.53, a decrease of 0.2%[25] - The company experienced a 51.20% decrease in cash and cash equivalents at the end of the period, totaling ¥43,677,650.00[10] - The company’s accounts receivable decreased from 133,730,179.27 CNY to 110,453,164.68 CNY[21] - The inventory increased slightly from 250,009,438.55 CNY to 252,959,098.35 CNY[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,353[14] - The largest shareholder, Wang Daixue, holds 21.83% of shares, totaling 107,537,613 shares, with 80,653,210 shares pledged[14] - The total number of restricted shares at the end of the period is 83,554,460, down from 85,958,375 at the beginning of the period[18] Research and Development - Research and development expenses for the period were ¥747,230.00, a decrease of 47.36% year-on-year, attributed to reduced investment in R&D projects[10] - The company has completed the consistency evaluation of the quality and efficacy of Iopamidol injection[19] - The company has obtained the drug registration certificate for Gadobutrol injection[19] - The company has changed the use of raised funds from the "Cangzhou solid preparation new workshop project" to the "Cangzhou Phase III raw material drug production project"[19] Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[24]